- Home
- ALAR vs SKYE Comparison
ALAR vs SKYE Comparison
Compare ALAR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- SKYE
- Stock Information
- Founded
- ALAR 2013
- SKYE 2012
- Country
- ALAR Israel
- SKYE United States
- Employees
- ALAR N/A
- SKYE N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- SKYE Health Care
- Exchange
- ALAR Nasdaq
- SKYE Nasdaq
- Market Cap
- ALAR 70.7M
- SKYE 108.3M
- IPO Year
- ALAR 2018
- SKYE N/A
- Fundamental
- Price
- ALAR $18.51
- SKYE $4.78
- Analyst Decision
- ALAR Strong Buy
- SKYE Buy
- Analyst Count
- ALAR 2
- SKYE 6
- Target Price
- ALAR $25.50
- SKYE $18.67
- AVG Volume (30 Days)
- ALAR 403.8K
- SKYE 330.3K
- Earning Date
- ALAR 11-26-2024
- SKYE 11-09-2024
- Dividend Yield
- ALAR N/A
- SKYE N/A
- EPS Growth
- ALAR N/A
- SKYE N/A
- EPS
- ALAR 0.07
- SKYE N/A
- Revenue
- ALAR $31,117,000.00
- SKYE N/A
- Revenue This Year
- ALAR $22.15
- SKYE N/A
- Revenue Next Year
- ALAR $11.59
- SKYE N/A
- P/E Ratio
- ALAR $29.65
- SKYE N/A
- Revenue Growth
- ALAR 52.26
- SKYE N/A
- 52 Week Low
- ALAR $2.92
- SKYE $1.44
- 52 Week High
- ALAR $46.69
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ALAR 70.83
- SKYE 53.92
- Support Level
- ALAR $8.97
- SKYE $3.53
- Resistance Level
- ALAR $21.50
- SKYE $4.53
- Average True Range (ATR)
- ALAR 1.53
- SKYE 0.41
- MACD
- ALAR 1.28
- SKYE 0.15
- Stochastic Oscillator
- ALAR 76.14
- SKYE 100.00
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.